Trials / Unknown
UnknownNCT04675008
Central Nervous System(CNS) Efficacy of Dacomitinib
A Phase II Study of Dacomitinib in Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer (NSCLC) Patients Who Have Non-irradiated Brain Metastasis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dacomitinib | Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis |
Timeline
- Start date
- 2020-12-07
- Primary completion
- 2022-09-01
- Completion
- 2023-03-01
- First posted
- 2020-12-19
- Last updated
- 2021-01-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04675008. Inclusion in this directory is not an endorsement.